Madrigal Pharmaceuticals, Inc. (MDGL) Stock Competitors & Peer Comparison
See (MDGL) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MDGL | $536.86 | +1.10% | 12.4B | -41.94 | -$12.80 | N/A |
| VRTX | $476.31 | -0.82% | 120.9B | 25.31 | $18.82 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $656.12 | -1.05% | 67.6B | 14.38 | $45.63 | +0.55% |
| ARGX | $859.43 | -1.92% | 53.4B | 77.57 | $11.08 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMDW | $8.98 | +0.22% | 39.9B | -2.20 | -$4.15 | N/A |
| RVMD | $184.97 | +0.55% | 39.3B | -26.16 | -$7.07 | N/A |
| ALNY | $281.26 | -2.36% | 37.6B | 50.68 | $5.55 | N/A |
| ONC | $306.56 | +0.86% | 32.8B | 68.58 | $4.47 | N/A |
Stock Comparison
MDGL vs VRTX Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, VRTX has a market cap of 120.9B. Regarding current trading prices, MDGL is priced at $536.86, while VRTX trades at $476.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas VRTX's P/E ratio is 25.31. In terms of profitability, MDGL's ROE is -0.50%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, MDGL is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check VRTX's competition here
MDGL vs VRNA Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, MDGL is priced at $536.86, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas VRNA's P/E ratio is -102.80. In terms of profitability, MDGL's ROE is -0.50%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, MDGL is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check VRNA's competition here
MDGL vs REGN Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, REGN has a market cap of 67.6B. Regarding current trading prices, MDGL is priced at $536.86, while REGN trades at $656.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas REGN's P/E ratio is 14.38. In terms of profitability, MDGL's ROE is -0.50%, compared to REGN's ROE of +0.14%. Regarding short-term risk, MDGL is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check REGN's competition here
MDGL vs ARGX Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, ARGX has a market cap of 53.4B. Regarding current trading prices, MDGL is priced at $536.86, while ARGX trades at $859.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas ARGX's P/E ratio is 77.57. In terms of profitability, MDGL's ROE is -0.50%, compared to ARGX's ROE of +0.22%. Regarding short-term risk, MDGL is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check ARGX's competition here
MDGL vs SGEN Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, MDGL is priced at $536.86, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas SGEN's P/E ratio is -57.19. In terms of profitability, MDGL's ROE is -0.50%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, MDGL is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check SGEN's competition here
MDGL vs RVMDW Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, RVMDW has a market cap of 39.9B. Regarding current trading prices, MDGL is priced at $536.86, while RVMDW trades at $8.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas RVMDW's P/E ratio is -2.20. In terms of profitability, MDGL's ROE is -0.50%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, MDGL is less volatile compared to RVMDW. This indicates potentially lower risk in terms of short-term price fluctuations for MDGL.Check RVMDW's competition here
MDGL vs RVMD Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, RVMD has a market cap of 39.3B. Regarding current trading prices, MDGL is priced at $536.86, while RVMD trades at $184.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas RVMD's P/E ratio is -26.16. In terms of profitability, MDGL's ROE is -0.50%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, MDGL is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check RVMD's competition here
MDGL vs ALNY Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, ALNY has a market cap of 37.6B. Regarding current trading prices, MDGL is priced at $536.86, while ALNY trades at $281.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas ALNY's P/E ratio is 50.68. In terms of profitability, MDGL's ROE is -0.50%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, MDGL is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check ALNY's competition here
MDGL vs ONC Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, ONC has a market cap of 32.8B. Regarding current trading prices, MDGL is priced at $536.86, while ONC trades at $306.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas ONC's P/E ratio is 68.58. In terms of profitability, MDGL's ROE is -0.50%, compared to ONC's ROE of +0.12%. Regarding short-term risk, MDGL is more volatile compared to ONC. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check ONC's competition here
MDGL vs MRNA Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, MRNA has a market cap of 26.8B. Regarding current trading prices, MDGL is priced at $536.86, while MRNA trades at $67.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas MRNA's P/E ratio is -8.27. In terms of profitability, MDGL's ROE is -0.50%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, MDGL is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check MRNA's competition here
MDGL vs ROIV Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, ROIV has a market cap of 25.1B. Regarding current trading prices, MDGL is priced at $536.86, while ROIV trades at $34.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas ROIV's P/E ratio is -35.88. In terms of profitability, MDGL's ROE is -0.50%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, MDGL is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check ROIV's competition here
MDGL vs INSM Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, INSM has a market cap of 23.9B. Regarding current trading prices, MDGL is priced at $536.86, while INSM trades at $110.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas INSM's P/E ratio is -19.15. In terms of profitability, MDGL's ROE is -0.50%, compared to INSM's ROE of -1.30%. Regarding short-term risk, MDGL is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check INSM's competition here
MDGL vs INCY Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, INCY has a market cap of 23B. Regarding current trading prices, MDGL is priced at $536.86, while INCY trades at $114.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas INCY's P/E ratio is 15.44. In terms of profitability, MDGL's ROE is -0.50%, compared to INCY's ROE of +0.29%. Regarding short-term risk, MDGL is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check INCY's competition here
MDGL vs BNTX Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, BNTX has a market cap of 22.9B. Regarding current trading prices, MDGL is priced at $536.86, while BNTX trades at $90.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas BNTX's P/E ratio is -19.57. In terms of profitability, MDGL's ROE is -0.50%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, MDGL is less volatile compared to BNTX. This indicates potentially lower risk in terms of short-term price fluctuations for MDGL.Check BNTX's competition here
MDGL vs UTHR Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, UTHR has a market cap of 22.4B. Regarding current trading prices, MDGL is priced at $536.86, while UTHR trades at $526.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas UTHR's P/E ratio is 19.44. In terms of profitability, MDGL's ROE is -0.50%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, MDGL is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check UTHR's competition here
MDGL vs BGNE Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, MDGL is priced at $536.86, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas BGNE's P/E ratio is -22.55. In terms of profitability, MDGL's ROE is -0.50%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, MDGL is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check BGNE's competition here
MDGL vs DNA-WT Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, MDGL is priced at $536.86, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, MDGL's ROE is -0.50%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, MDGL is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for MDGL.Check DNA-WT's competition here
MDGL vs GMAB Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, GMAB has a market cap of 17.6B. Regarding current trading prices, MDGL is priced at $536.86, while GMAB trades at $28.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas GMAB's P/E ratio is 20.67. In terms of profitability, MDGL's ROE is -0.50%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, MDGL is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check GMAB's competition here
MDGL vs NBIX Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, NBIX has a market cap of 17.3B. Regarding current trading prices, MDGL is priced at $536.86, while NBIX trades at $172.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas NBIX's P/E ratio is 24.85. In terms of profitability, MDGL's ROE is -0.50%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, MDGL is less volatile compared to NBIX. This indicates potentially lower risk in terms of short-term price fluctuations for MDGL.Check NBIX's competition here
MDGL vs ASND Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, ASND has a market cap of 16.5B. Regarding current trading prices, MDGL is priced at $536.86, while ASND trades at $265.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas ASND's P/E ratio is -109.74. In terms of profitability, MDGL's ROE is -0.50%, compared to ASND's ROE of -56.42%. Regarding short-term risk, MDGL is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check ASND's competition here
MDGL vs BBIO Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, BBIO has a market cap of 16.5B. Regarding current trading prices, MDGL is priced at $536.86, while BBIO trades at $84.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas BBIO's P/E ratio is -22.48. In terms of profitability, MDGL's ROE is -0.50%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, MDGL is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for MDGL.Check BBIO's competition here
MDGL vs JAZZ Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, JAZZ has a market cap of 15B. Regarding current trading prices, MDGL is priced at $536.86, while JAZZ trades at $238.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas JAZZ's P/E ratio is 18.51. In terms of profitability, MDGL's ROE is -0.50%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, MDGL is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check JAZZ's competition here
MDGL vs EXEL Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, EXEL has a market cap of 14B. Regarding current trading prices, MDGL is priced at $536.86, while EXEL trades at $55.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas EXEL's P/E ratio is 16.70. In terms of profitability, MDGL's ROE is -0.50%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, MDGL is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check EXEL's competition here
MDGL vs KRTX Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, MDGL is priced at $536.86, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas KRTX's P/E ratio is -28.09. In terms of profitability, MDGL's ROE is -0.50%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, MDGL is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check KRTX's competition here
MDGL vs AXSM Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, AXSM has a market cap of 12.1B. Regarding current trading prices, MDGL is priced at $536.86, while AXSM trades at $235.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas AXSM's P/E ratio is -61.43. In terms of profitability, MDGL's ROE is -0.50%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, MDGL is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for MDGL.Check AXSM's competition here
MDGL vs SMMT Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, SMMT has a market cap of 12B. Regarding current trading prices, MDGL is priced at $536.86, while SMMT trades at $15.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas SMMT's P/E ratio is -9.67. In terms of profitability, MDGL's ROE is -0.50%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, MDGL is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check SMMT's competition here
MDGL vs BMRN Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, BMRN has a market cap of 11.3B. Regarding current trading prices, MDGL is priced at $536.86, while BMRN trades at $58.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas BMRN's P/E ratio is 28.19. In terms of profitability, MDGL's ROE is -0.50%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, MDGL is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check BMRN's competition here
MDGL vs RNAM Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, MDGL is priced at $536.86, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas RNAM's P/E ratio is -17.39. In terms of profitability, MDGL's ROE is -0.50%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, MDGL is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check RNAM's competition here
MDGL vs TECH Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, TECH has a market cap of 11.2B. Regarding current trading prices, MDGL is priced at $536.86, while TECH trades at $71.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas TECH's P/E ratio is 36.72. In terms of profitability, MDGL's ROE is -0.50%, compared to TECH's ROE of +0.05%. Regarding short-term risk, MDGL is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check TECH's competition here
MDGL vs CYTK Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, CYTK has a market cap of 10.2B. Regarding current trading prices, MDGL is priced at $536.86, while CYTK trades at $81.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas CYTK's P/E ratio is -14.05. In terms of profitability, MDGL's ROE is -0.50%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, MDGL is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for MDGL.Check CYTK's competition here
MDGL vs ARWR Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, ARWR has a market cap of 10.1B. Regarding current trading prices, MDGL is priced at $536.86, while ARWR trades at $71.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas ARWR's P/E ratio is -33.45. In terms of profitability, MDGL's ROE is -0.50%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, MDGL is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for MDGL.Check ARWR's competition here
MDGL vs KRYS Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, KRYS has a market cap of 10B. Regarding current trading prices, MDGL is priced at $536.86, while KRYS trades at $339.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas KRYS's P/E ratio is 45.38. In terms of profitability, MDGL's ROE is -0.50%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, MDGL is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for MDGL.Check KRYS's competition here
MDGL vs ABVX Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, ABVX has a market cap of 9.9B. Regarding current trading prices, MDGL is priced at $536.86, while ABVX trades at $134.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas ABVX's P/E ratio is -70.72. In terms of profitability, MDGL's ROE is -0.50%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, MDGL is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check ABVX's competition here
MDGL vs CORT Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, CORT has a market cap of 9.7B. Regarding current trading prices, MDGL is priced at $536.86, while CORT trades at $90.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas CORT's P/E ratio is 258.49. In terms of profitability, MDGL's ROE is -0.50%, compared to CORT's ROE of +0.08%. Regarding short-term risk, MDGL is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for MDGL.Check CORT's competition here
MDGL vs RXDX Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, MDGL is priced at $536.86, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas RXDX's P/E ratio is -56.47. In terms of profitability, MDGL's ROE is -0.50%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, MDGL is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check RXDX's competition here
MDGL vs KYMR Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, KYMR has a market cap of 9.2B. Regarding current trading prices, MDGL is priced at $536.86, while KYMR trades at $112.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas KYMR's P/E ratio is -31.75. In terms of profitability, MDGL's ROE is -0.50%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, MDGL is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check KYMR's competition here
MDGL vs NUVL Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, MDGL is priced at $536.86, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas NUVL's P/E ratio is -21.79. In terms of profitability, MDGL's ROE is -0.50%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, MDGL is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check NUVL's competition here
MDGL vs IONS Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, IONS has a market cap of 9.1B. Regarding current trading prices, MDGL is priced at $536.86, while IONS trades at $54.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas IONS's P/E ratio is -31.94. In terms of profitability, MDGL's ROE is -0.50%, compared to IONS's ROE of -0.59%. Regarding short-term risk, MDGL is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for MDGL.Check IONS's competition here
MDGL vs HALO Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, HALO has a market cap of 8.9B. Regarding current trading prices, MDGL is priced at $536.86, while HALO trades at $75.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas HALO's P/E ratio is 16.24. In terms of profitability, MDGL's ROE is -0.50%, compared to HALO's ROE of +1.26%. Regarding short-term risk, MDGL is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check HALO's competition here
MDGL vs CRNX Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, CRNX has a market cap of 8.9B. Regarding current trading prices, MDGL is priced at $536.86, while CRNX trades at $83.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas CRNX's P/E ratio is -16.32. In terms of profitability, MDGL's ROE is -0.50%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, MDGL is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check CRNX's competition here
MDGL vs IMGN Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, MDGL is priced at $536.86, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas IMGN's P/E ratio is -111.55. In terms of profitability, MDGL's ROE is -0.50%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, MDGL is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check IMGN's competition here
MDGL vs ALKS Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, ALKS has a market cap of 8.6B. Regarding current trading prices, MDGL is priced at $536.86, while ALKS trades at $51.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas ALKS's P/E ratio is 54.32. In terms of profitability, MDGL's ROE is -0.50%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, MDGL is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check ALKS's competition here
MDGL vs PTGX Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, PTGX has a market cap of 8.4B. Regarding current trading prices, MDGL is priced at $536.86, while PTGX trades at $131.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas PTGX's P/E ratio is -72.52. In terms of profitability, MDGL's ROE is -0.50%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, MDGL is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check PTGX's competition here
MDGL vs TGTX Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, TGTX has a market cap of 8.4B. Regarding current trading prices, MDGL is priced at $536.86, while TGTX trades at $54.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas TGTX's P/E ratio is 18.86. In terms of profitability, MDGL's ROE is -0.50%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, MDGL is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check TGTX's competition here
MDGL vs BPMC Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, MDGL is priced at $536.86, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas BPMC's P/E ratio is -51.58. In terms of profitability, MDGL's ROE is -0.50%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, MDGL is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check BPMC's competition here
MDGL vs APGE Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, MDGL is priced at $536.86, while APGE trades at $133.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas APGE's P/E ratio is -30.94. In terms of profitability, MDGL's ROE is -0.50%, compared to APGE's ROE of -0.33%. Regarding short-term risk, MDGL is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check APGE's competition here
MDGL vs IBRX Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, IBRX has a market cap of 8.3B. Regarding current trading prices, MDGL is priced at $536.86, while IBRX trades at $7.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas IBRX's P/E ratio is -24.62. In terms of profitability, MDGL's ROE is -0.50%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, MDGL is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for MDGL.Check IBRX's competition here
MDGL vs CERE Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, MDGL is priced at $536.86, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas CERE's P/E ratio is -16.47. In terms of profitability, MDGL's ROE is -0.50%, compared to CERE's ROE of -0.72%. Regarding short-term risk, MDGL is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check CERE's competition here
MDGL vs PCVX Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, PCVX has a market cap of 8.1B. Regarding current trading prices, MDGL is priced at $536.86, while PCVX trades at $56.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas PCVX's P/E ratio is -8.17. In terms of profitability, MDGL's ROE is -0.50%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, MDGL is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for MDGL.Check PCVX's competition here
MDGL vs IMVT Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, IMVT has a market cap of 8B. Regarding current trading prices, MDGL is priced at $536.86, while IMVT trades at $38.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas IMVT's P/E ratio is -14.52. In terms of profitability, MDGL's ROE is -0.50%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, MDGL is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check IMVT's competition here
MDGL vs RYTM Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, RYTM has a market cap of 7.5B. Regarding current trading prices, MDGL is priced at $536.86, while RYTM trades at $109.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas RYTM's P/E ratio is -35.13. In terms of profitability, MDGL's ROE is -0.50%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, MDGL is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for MDGL.Check RYTM's competition here
MDGL vs MTSR Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, MDGL is priced at $536.86, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas MTSR's P/E ratio is -23.58. In terms of profitability, MDGL's ROE is -0.50%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, MDGL is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check MTSR's competition here
MDGL vs PRAX Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, PRAX has a market cap of 6.9B. Regarding current trading prices, MDGL is priced at $536.86, while PRAX trades at $327.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas PRAX's P/E ratio is -24.51. In terms of profitability, MDGL's ROE is -0.50%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, MDGL is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for MDGL.Check PRAX's competition here
MDGL vs MRUS Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, MDGL is priced at $536.86, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas MRUS's P/E ratio is -17.05. In terms of profitability, MDGL's ROE is -0.50%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, MDGL is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check MRUS's competition here
MDGL vs LQDA Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, LQDA has a market cap of 6.8B. Regarding current trading prices, MDGL is priced at $536.86, while LQDA trades at $76.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas LQDA's P/E ratio is 546.36. In terms of profitability, MDGL's ROE is -0.50%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, MDGL is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for MDGL.Check LQDA's competition here
MDGL vs ACLX Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, MDGL is priced at $536.86, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas ACLX's P/E ratio is -28.27. In terms of profitability, MDGL's ROE is -0.50%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, MDGL is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check ACLX's competition here
MDGL vs COGT Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, COGT has a market cap of 6.6B. Regarding current trading prices, MDGL is priced at $536.86, while COGT trades at $38.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas COGT's P/E ratio is -18.25. In terms of profitability, MDGL's ROE is -0.50%, compared to COGT's ROE of -0.83%. Regarding short-term risk, MDGL is less volatile compared to COGT. This indicates potentially lower risk in terms of short-term price fluctuations for MDGL.Check COGT's competition here
MDGL vs RETA Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, MDGL is priced at $536.86, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas RETA's P/E ratio is -66.29. In terms of profitability, MDGL's ROE is -0.50%, compared to RETA's ROE of +0.47%. Regarding short-term risk, MDGL is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check RETA's competition here
MDGL vs PTCT Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, PTCT has a market cap of 6.5B. Regarding current trading prices, MDGL is priced at $536.86, while PTCT trades at $78.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas PTCT's P/E ratio is -33.50. In terms of profitability, MDGL's ROE is -0.50%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, MDGL is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for MDGL.Check PTCT's competition here
MDGL vs SRRK Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, SRRK has a market cap of 6.4B. Regarding current trading prices, MDGL is priced at $536.86, while SRRK trades at $53.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas SRRK's P/E ratio is -14.98. In terms of profitability, MDGL's ROE is -0.50%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, MDGL is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for MDGL.Check SRRK's competition here
MDGL vs CGON Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, CGON has a market cap of 6.3B. Regarding current trading prices, MDGL is priced at $536.86, while CGON trades at $71.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas CGON's P/E ratio is -30.80. In terms of profitability, MDGL's ROE is -0.50%, compared to CGON's ROE of -0.23%. Regarding short-term risk, MDGL is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for MDGL.Check CGON's competition here
MDGL vs CNTA Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, MDGL is priced at $536.86, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas CNTA's P/E ratio is -22.63. In terms of profitability, MDGL's ROE is -0.50%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, MDGL is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check CNTA's competition here
MDGL vs MIRM Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, MIRM has a market cap of 6.1B. Regarding current trading prices, MDGL is priced at $536.86, while MIRM trades at $120.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas MIRM's P/E ratio is -8.88. In terms of profitability, MDGL's ROE is -0.50%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, MDGL is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for MDGL.Check MIRM's competition here
MDGL vs ERAS Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, ERAS has a market cap of 6.1B. Regarding current trading prices, MDGL is priced at $536.86, while ERAS trades at $19.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas ERAS's P/E ratio is -44.32. In terms of profitability, MDGL's ROE is -0.50%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, MDGL is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for MDGL.Check ERAS's competition here
MDGL vs LGND Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, LGND has a market cap of 6B. Regarding current trading prices, MDGL is priced at $536.86, while LGND trades at $300.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas LGND's P/E ratio is 36.09. In terms of profitability, MDGL's ROE is -0.50%, compared to LGND's ROE of +0.16%. Regarding short-term risk, MDGL is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check LGND's competition here
MDGL vs SYRE Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, SYRE has a market cap of 6B. Regarding current trading prices, MDGL is priced at $536.86, while SYRE trades at $98.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas SYRE's P/E ratio is -47.57. In terms of profitability, MDGL's ROE is -0.50%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, MDGL is less volatile compared to SYRE. This indicates potentially lower risk in terms of short-term price fluctuations for MDGL.Check SYRE's competition here
MDGL vs BLTE Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, BLTE has a market cap of 5.9B. Regarding current trading prices, MDGL is priced at $536.86, while BLTE trades at $146.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas BLTE's P/E ratio is -78.44. In terms of profitability, MDGL's ROE is -0.50%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, MDGL is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check BLTE's competition here
MDGL vs CDTX Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, MDGL is priced at $536.86, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas CDTX's P/E ratio is -19.77. In terms of profitability, MDGL's ROE is -0.50%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, MDGL is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check CDTX's competition here
MDGL vs ABCM Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, MDGL is priced at $536.86, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, MDGL's ROE is -0.50%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, MDGL is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check ABCM's competition here
MDGL vs ISEE Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, MDGL is priced at $536.86, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas ISEE's P/E ratio is -22.44. In terms of profitability, MDGL's ROE is -0.50%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, MDGL is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check ISEE's competition here
MDGL vs CELC Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, CELC has a market cap of 5.4B. Regarding current trading prices, MDGL is priced at $536.86, while CELC trades at $111.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas CELC's P/E ratio is -28.47. In terms of profitability, MDGL's ROE is -0.50%, compared to CELC's ROE of -2.45%. Regarding short-term risk, MDGL is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for MDGL.Check CELC's competition here
MDGL vs XENE Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, XENE has a market cap of 5.3B. Regarding current trading prices, MDGL is priced at $536.86, while XENE trades at $67.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas XENE's P/E ratio is -14.32. In terms of profitability, MDGL's ROE is -0.50%, compared to XENE's ROE of -0.49%. Regarding short-term risk, MDGL is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check XENE's competition here
MDGL vs TVTX Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, TVTX has a market cap of 5.3B. Regarding current trading prices, MDGL is priced at $536.86, while TVTX trades at $57.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas TVTX's P/E ratio is -259.36. In terms of profitability, MDGL's ROE is -0.50%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, MDGL is more volatile compared to TVTX. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check TVTX's competition here
MDGL vs APLS Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, MDGL is priced at $536.86, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas APLS's P/E ratio is 38.35. In terms of profitability, MDGL's ROE is -0.50%, compared to APLS's ROE of +0.40%. Regarding short-term risk, MDGL is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check APLS's competition here
MDGL vs DFTX Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, DFTX has a market cap of 5B. Regarding current trading prices, MDGL is priced at $536.86, while DFTX trades at $45.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas DFTX's P/E ratio is N/A. In terms of profitability, MDGL's ROE is -0.50%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, MDGL is less volatile compared to DFTX. This indicates potentially lower risk in terms of short-term price fluctuations for MDGL.Check DFTX's competition here
MDGL vs CRSP Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, CRSP has a market cap of 4.9B. Regarding current trading prices, MDGL is priced at $536.86, while CRSP trades at $50.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas CRSP's P/E ratio is -9.87. In terms of profitability, MDGL's ROE is -0.50%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, MDGL is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for MDGL.Check CRSP's competition here
MDGL vs CAI Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, CAI has a market cap of 4.8B. Regarding current trading prices, MDGL is priced at $536.86, while CAI trades at $16.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas CAI's P/E ratio is -93.23. In terms of profitability, MDGL's ROE is -0.50%, compared to CAI's ROE of +0.06%. Regarding short-term risk, MDGL is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for MDGL.Check CAI's competition here
MDGL vs TERN Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, MDGL is priced at $536.86, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas TERN's P/E ratio is -51.41. In terms of profitability, MDGL's ROE is -0.50%, compared to TERN's ROE of -0.20%. Regarding short-term risk, MDGL is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check TERN's competition here
MDGL vs LEGN Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, LEGN has a market cap of 4.7B. Regarding current trading prices, MDGL is priced at $536.86, while LEGN trades at $25.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas LEGN's P/E ratio is -37.75. In terms of profitability, MDGL's ROE is -0.50%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, MDGL is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check LEGN's competition here
MDGL vs MANE Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, MANE has a market cap of 4.6B. Regarding current trading prices, MDGL is priced at $536.86, while MANE trades at $110.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas MANE's P/E ratio is -34.99. In terms of profitability, MDGL's ROE is -0.50%, compared to MANE's ROE of -0.84%. Regarding short-term risk, MDGL is less volatile compared to MANE. This indicates potentially lower risk in terms of short-term price fluctuations for MDGL.Check MANE's competition here
MDGL vs FOLD Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, MDGL is priced at $536.86, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas FOLD's P/E ratio is -161.00. In terms of profitability, MDGL's ROE is -0.50%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, MDGL is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check FOLD's competition here
MDGL vs AKRO Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, MDGL is priced at $536.86, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas AKRO's P/E ratio is -14.57. In terms of profitability, MDGL's ROE is -0.50%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, MDGL is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check AKRO's competition here
MDGL vs ALPN Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, MDGL is priced at $536.86, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas ALPN's P/E ratio is -101.52. In terms of profitability, MDGL's ROE is -0.50%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, MDGL is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check ALPN's competition here
MDGL vs VKTX Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, VKTX has a market cap of 4.4B. Regarding current trading prices, MDGL is priced at $536.86, while VKTX trades at $37.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas VKTX's P/E ratio is -9.17. In terms of profitability, MDGL's ROE is -0.50%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, MDGL is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for MDGL.Check VKTX's competition here
MDGL vs ACAD Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, ACAD has a market cap of 4.4B. Regarding current trading prices, MDGL is priced at $536.86, while ACAD trades at $25.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas ACAD's P/E ratio is 12.50. In terms of profitability, MDGL's ROE is -0.50%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, MDGL is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check ACAD's competition here
MDGL vs EWTX Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, EWTX has a market cap of 4.3B. Regarding current trading prices, MDGL is priced at $536.86, while EWTX trades at $39.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas EWTX's P/E ratio is -23.93. In terms of profitability, MDGL's ROE is -0.50%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, MDGL is less volatile compared to EWTX. This indicates potentially lower risk in terms of short-term price fluctuations for MDGL.Check EWTX's competition here
MDGL vs OPT Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, MDGL is priced at $536.86, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas OPT's P/E ratio is -1.52. In terms of profitability, MDGL's ROE is -0.50%, compared to OPT's ROE of +1.18%. Regarding short-term risk, MDGL is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check OPT's competition here
MDGL vs DNTH Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, DNTH has a market cap of 4.2B. Regarding current trading prices, MDGL is priced at $536.86, while DNTH trades at $101.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas DNTH's P/E ratio is -24.54. In terms of profitability, MDGL's ROE is -0.50%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, MDGL is less volatile compared to DNTH. This indicates potentially lower risk in terms of short-term price fluctuations for MDGL.Check DNTH's competition here
MDGL vs NAMSW Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, NAMSW has a market cap of 4.1B. Regarding current trading prices, MDGL is priced at $536.86, while NAMSW trades at $24.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas NAMSW's P/E ratio is -13.76. In terms of profitability, MDGL's ROE is -0.50%, compared to NAMSW's ROE of -0.30%. Regarding short-term risk, MDGL is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check NAMSW's competition here
MDGL vs MRTX Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, MDGL is priced at $536.86, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas MRTX's P/E ratio is -4.82. In terms of profitability, MDGL's ROE is -0.50%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, MDGL is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check MRTX's competition here
MDGL vs DYN Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, DYN has a market cap of 3.9B. Regarding current trading prices, MDGL is priced at $536.86, while DYN trades at $23.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas DYN's P/E ratio is -7.39. In terms of profitability, MDGL's ROE is -0.50%, compared to DYN's ROE of -0.58%. Regarding short-term risk, MDGL is less volatile compared to DYN. This indicates potentially lower risk in terms of short-term price fluctuations for MDGL.Check DYN's competition here
MDGL vs NAMS Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, NAMS has a market cap of 3.9B. Regarding current trading prices, MDGL is priced at $536.86, while NAMS trades at $33.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas NAMS's P/E ratio is -20.94. In terms of profitability, MDGL's ROE is -0.50%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, MDGL is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for MDGL.Check NAMS's competition here
MDGL vs CPRX Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, MDGL is priced at $536.86, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas CPRX's P/E ratio is 11.33. In terms of profitability, MDGL's ROE is -0.50%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, MDGL is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check CPRX's competition here
MDGL vs RYZB Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, MDGL is priced at $536.86, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas RYZB's P/E ratio is -57.86. In terms of profitability, MDGL's ROE is -0.50%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, MDGL is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check RYZB's competition here
MDGL vs TLX Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, TLX has a market cap of 3.7B. Regarding current trading prices, MDGL is priced at $536.86, while TLX trades at $11.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas TLX's P/E ratio is -598.91. In terms of profitability, MDGL's ROE is -0.50%, compared to TLX's ROE of -0.02%. Regarding short-term risk, MDGL is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check TLX's competition here
MDGL vs CBAY Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, MDGL is priced at $536.86, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas CBAY's P/E ratio is -32.81. In terms of profitability, MDGL's ROE is -0.50%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, MDGL is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for MDGL.Check CBAY's competition here
MDGL vs ELVN Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, ELVN has a market cap of 3.7B. Regarding current trading prices, MDGL is priced at $536.86, while ELVN trades at $51.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas ELVN's P/E ratio is -30.98. In terms of profitability, MDGL's ROE is -0.50%, compared to ELVN's ROE of -0.21%. Regarding short-term risk, MDGL is less volatile compared to ELVN. This indicates potentially lower risk in terms of short-term price fluctuations for MDGL.Check ELVN's competition here
MDGL vs TNGX Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, TNGX has a market cap of 3.7B. Regarding current trading prices, MDGL is priced at $536.86, while TNGX trades at $29.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas TNGX's P/E ratio is -35.72. In terms of profitability, MDGL's ROE is -0.50%, compared to TNGX's ROE of -0.42%. Regarding short-term risk, MDGL is less volatile compared to TNGX. This indicates potentially lower risk in terms of short-term price fluctuations for MDGL.Check TNGX's competition here
MDGL vs DNLI Comparison July 2026
MDGL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MDGL stands at 12.4B. In comparison, DNLI has a market cap of 3.6B. Regarding current trading prices, MDGL is priced at $536.86, while DNLI trades at $22.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MDGL currently has a P/E ratio of -41.94, whereas DNLI's P/E ratio is -7.86. In terms of profitability, MDGL's ROE is -0.50%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, MDGL is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for MDGL.Check DNLI's competition here